Moreover, in a retrospective analysis of four randomized phase III trials, the overall prevalence of RET rearrangements identified was 0.7% and none of the three RET-positive NSCLC patients have obtained an OR after treatment with vandetanib [65]. This evidence concerns the gene RET and non-small cell lung carcinoma.